Morphiex is harnessing the power of the immune system to fight cancer by developing the only dual-functioning #CD47 immune checkpoint inhibitor. Our lead drug candidate, MBT-001, blocks both "don't eat me" and thrombospondin-1 (TSP-1) pathways of #CD47. This enables direct tumor cell killing mediated by T cells, Natural Killer cells, Neutrophils as well as Macrophages.
MBT-001 was developed at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) and is exclusively licensed to Morphiex for the treatment of cancer as a monotherapy or in combination with other modalities such as chemotherapy, immune checkpoint inhibitors, CAR-T and many others. Morphiex has entered into a cooperative research and development agreement (CRADA) with the NIH/NCI to accelerate the development of MBT-001.
Location: United States, Massachusetts, Boston
Member count: 1-10
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Xontogeny | xontogeny.... |